Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.57 |
| ▸ | DRD4 | P21917 | 10/20 | 0.57 |
| ▸ | DRD3 | P35462 | 10/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033030 | 0.84 | DRD2 (0.57) | DRD2DRD4DRD3HTR1AKCNH2 | |
| SCHEMBL3028462 | 0.80 | DRD2 (0.80) | DRD2DRD4DRD3 | |
| SCHEMBL3024745 | 0.78 | DRD2 (0.79) | DRD2DRD4DRD3OPRM1 | |
| SCHEMBL3033909 | 0.78 | DRD2 (0.60) | DRD2DRD4DRD3HTR1AKMT2A | |
| SCHEMBL19596737 | 0.72 | DRD2 (0.71) | DRD2DRD4DRD3FAAHHTR2A | |
| SCHEMBL17898231 | 0.71 | DRD3 (0.60) | DRD2DRD4DRD3HTR2AHTR7 | |
| SCHEMBL2702018 | 0.71 | DRD2 (1.00) | DRD2DRD4DRD3ACHEHTR1D | |
| SCHEMBL8394614 | 0.71 | DRD2 (1.00) | DRD2DRD4DRD3ACHEHTR1D | |
| SCHEMBL2701521 | 0.71 | DRD2 (1.00) | DRD2DRD4DRD3ACHEHTR1D | |
| Hydrochloric Acid SCHEMBL6339640 | 0.70 | DRD2 (0.97) | DRD2DRD4DRD3ACHEHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227604-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | WAYNE STATE UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-7723519-B2 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| US-6982332-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-03 | — | — | US | disclosed |
| US-20030195219-A1 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity | WAYNE STATE UNIVERSITY | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195219-A1 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity | HTR3A, HTR3C, HTR2C | DRD2 5/4885DRD4 28/4885DRD3 7/4885 |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | HTR3A, HTR3C, HTR2C | DRD2 5/4885DRD4 29/4885DRD3 7/4885 |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | HTR3A, DRD3, DRD2 | DRD2 3/4885DRD4 12/4885DRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.